Sean Duffy Sells 14,158 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,158 shares of Omada Health stock in a transaction on Friday, June 26th. The shares were sold at an average price of $20.00, for a total transaction of $283,160.00. Following the sale, the chief executive officer directly owned 394,603 shares of the company’s stock, valued at $7,892,060. This trade represents a 3.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Omada Health Stock Up 10.5%

Shares of Omada Health stock traded up $1.99 during trading on Friday, hitting $20.89. 3,310,497 shares of the stock traded hands, compared to its average volume of 946,807. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92. The company has a fifty day moving average price of $16.51 and a two-hundred day moving average price of $14.85.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. On average, equities research analysts expect that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. The Goldman Sachs Group restated a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Omada Health in a research report on Thursday, June 4th. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Omada Health in a report on Friday, May 8th. Citizens Jmp boosted their price target on Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $30.00 price target on shares of Omada Health in a research note on Monday. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.91.

Institutional Trading of Omada Health

A number of institutional investors and hedge funds have recently modified their holdings of OMDA. Raymond James Financial Inc. bought a new stake in shares of Omada Health during the 2nd quarter worth $32,000. Quarry LP bought a new position in Omada Health in the 4th quarter worth $29,000. TD Waterhouse Canada Inc. acquired a new position in Omada Health during the 4th quarter worth $32,000. Inlight Wealth Management LLC acquired a new stake in shares of Omada Health in the fourth quarter valued at about $45,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Omada Health in the third quarter worth about $82,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.